Back to Browse Journals » Patient Preference and Adherence » Volume 2

Patient’s compliance with allergen immunotherapy

Authors Cristoforo Incorvaia, Marina Mauro, Erminia Ridolo, Paola Puccinelli, Massimiliano Liuzzo, et al

Published Date September 2008 Volume 2008:2 Pages 247—251

DOI http://dx.doi.org/10.2147/PPA.S3806

Published 15 September 2008

Cristoforo Incorvaia1, Marina Mauro2, Erminia Ridolo3, Paola Puccinelli4, Massimiliano Liuzzo4, Silvia Scurati4, Franco Frati4,5

1Allergy/Pulmonary rehabilitation Unit, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University Department of Clinical Sciences, Parma, Italy; 4Medical and Scientific Department, Stallergenes, Milan, Italy; 5Pediatrics, University Department of Medical and Surgical Specialty and Public Health, Perugia, Italy

Background: Allergen immunotherapy (IT) is an effective treatment of respiratory allergy, but requires strict rules of performance. This makes compliance particularly relevant, but thus far only a few studies have investigated this issue.

Methods: We reviewed all the available articles on compliance and adherence with IT in its different forms of administration, ie, subcutaneous (SCIT), sublingual (SLIT), and local nasal (LNIT).

Results: Early studies, when only SCIT was available, reported a low compliance, ranging from 45% to 60%, but the demanding schedules used, with very frequent injections, accounted for this outcome, as shown by patients’ recognition of inconvenience as the major cause of noncompliance. The most recent studies reported a good compliance, estimated in 75% to 90%, to both SCIT and SLIT, inconvenience remaining the major cause of noncompliance, followed by cost of the treatment. The only study addressing LNIT found a very poor compliance (27%), the major cause being the side effects, with repeated nasal reactions to the allergen extract.

Conclusions: Adequate education of patients and optimization of administration schedules, with fine balancing between dose effectiveness and cost, are the factors most likely to achieve further improvement of compliance with IT.

Keywords: allergen immunotherapy, subcutaneous, sublingual, local nasal, compliance, adherence

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Effect of noninvasive mechanical ventilation in elderly patients with hypercapnic acute-on-chronic respiratory failure and a do-not-intubate order

Paolo Scarpazza, Cristoforo Incorvaia, Giuseppe di Franco, Stefania Raschi, Pierfranco Usai, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:797-801

Published Date: 30 October 2008

Current and future applications of the anti-IgE antibody omalizumab

Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini

Biologics: Targets and Therapy 2008, 2:67-73

Published Date: 26 March 2008

Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium

Cristoforo Incorvaia, Gian Galeazzo Riario-Sforza, Chiara Pravettoni, Mona-Rita Yacoub, Franco Frati

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:123-126

Published Date: 18 March 2008

Readers of this article also read:

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

Progressive osseous heteroplasia: diagnosis, treatment, and prognosis

Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS

The Application of Clinical Genetics 2015, 8:37-48

Published Date: 30 January 2015

Diabetes reversal via gene transfer: building on successes in animal models

Gerace D, Martiniello-Wilks R, Simpson AM

Research and Reports in Endocrine Disorders 2015, 5:15-29

Published Date: 29 January 2015

Corneal laceration caused by river crab

Vinuthinee N, Azreen-Redzal A, Juanarita J, Zunaina E

Clinical Ophthalmology 2015, 9:203-206

Published Date: 29 January 2015

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Nanodrugs: optimism for emerging trend of multidrug resistance

Khan AU

International Journal of Nanomedicine 2012, 7:4323-4324

Published Date: 6 August 2012

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012